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Objectives. The goals of this study were to determine the 
probability of successful defibrillation at the upper limit of 
vulnerability and to evaluate a minimal safety margin for implant- 
able cardioverter-defibrillator first shocks based solely on the 
upper limit of vulnerability. 
Background. The upper limit of vulnerability is the strength at 
or above which ventricular fibrillation is not induced when a 
stimulus is delivered uring the vulnerable phase of the cardiac 
cycle. It has been proposed as an estimate of defibrillation efficacy 
because it correlates with the defibrillation threshold and can be 
determined with a single episode of fibrillation. 
Methods. We studied 40 patients prospectively atimplantation 
of transvenous cardioverter-defibrillators. Defibrillation thresh- 
old was defined as the weakest biphasic shock that defibrillated 
after 10 s of ventricular fibrillation. The upper limit of vulnera- 
bility was defined as the weakest biphasic shock that did not 
induce ventricular fibrillation when given at 0, 20 and 40 ms 
before the peak of the T wave in ventricular paced rhythm at cycle 
length 500 ms. Mter determination f the upper limit of vulner- 
ability and defibrillation threshold, patients underwent six addi- 
tional fibrillation-defibrillation episodes. The strength of five of 
the defibrillation shocks was equal to the upper limit of vulnera- 
bility; the strength of one of the six shocks was randomly selected 
to be equal to the upper limit of vulnerability plus 3 J. The 
implantable cardioverter-defibrillator was tested at the upper 
limit of vulnerability plus 3 J in 28 patients. 
Results. The defibrillation threshold was 8.8 -+ 5.0 J (mean -+ 
SD), and the upper limit of vulnerability was 11.3 +- 4.6 J; the 
defibrillation threshold and upper limit of vulnerability were 
highly correlated (r = 0.89, p < 0.001). The success rate for the 
200 defibrillation shocks with strength equal to the upper limit of 
vulnerability was 90% (95% confidence intervals based on propor- 
tion of successes in40 patients: 86% to 94%). All five defibrillation 
test shocks at the upper limit of vulnerability were successful in 24 
patients (60%); four of five were successful in 12 patients (30%); 
and three of five were successful in 4 patients (10%). All 40 test 
shocks and 28 implantable cardioverter-defibrillator shocks with 
a strength equal to the upper limit of vulnerability plus 3 J were 
successful. 
Conclusions. The upper limit of vulnerability is a good estima- 
tor of the shock strength associated with 90% probability of 
successful defibrillation (DFT90). A strength of 3 J above the 
upper limit of vulnerability is a good estimate of the minimal 
acute safety margin for implantable cardioverter-defibrillator 
first shocks. 
(JAm Coil Cardiol 1996;27:1112-8) 
An accurate measure of defibrillation efficacy that requires a 
minimal number of fibrillation episodes would be valuable in 
research studies and clinical practice. The upper limit of 
vulnerability is the strength at or above which ventricular 
fibrillation is not induced when a stimulus is delivered uring 
the vulnerable phase of the cardiac cycle. Previous studies 
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(1-5) have demonstrated a significant correlation between the 
upper limit of vulnerability in paced rhythms and the defibril- 
lation threshold. However, because these studies focused on 
establishing a correlation between the upper limit of vulnera- 
bility and the defibrillation threshold, they did not determine 
whether the upper limit of vulnerability identifies a shock 
strength associated with a predictable probability of defibrilla- 
tion. 
In patients with transvenous implantable cardioverter- 
defibrillators, a clinically applicable measure of the upper 
limit of vulnerability has been shown (5) to correlate with 
the defibrillation threshold. The goals of the present pro- 
spective study were to determine the probability of success- 
ful defibrillation at the upper limit of vulnerability and 
to evaluate a minimal safety margin for implantable 
cardioverter-defibrillator first shocks based solely on the 
upper limit of vulnerability. 
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Methods  
Patients. Forty-one of 48 consecutive patients gave written 
informed consent according to a protocol approved by the 
Human Subjects Committees of each institution. One patient 
with severe left ventricular dysfunction was excluded because 
he developed hypotension after induction of anesthesia and 
before implantable cardioverter-defibrillator implantation. 
The remaining 40 study patients included 28 men and 12 
women with a mean age of 64 _+ 13 years (range 24 to 78). The 
mean left ventricular ejection fraction was 0.32 _+ 0.11. 
Twenty-seven patients had coronary artery disease; 11 had 
myocardial or valvular disease; and 2 had idiopathic long QT 
syndrome. The clinical arrhythmia was sustained monomor- 
phic ventricular tachycardia in 24 patients, ustained polymor- 
phic ventricular tachyeardia in 1 and ventrieular fibrillation in 
15. Antiarrhythmic drugs had been discontinued for 5 half-lives 
except for digoxin (13 patients), beta-adrenergic blocking 
agents (8 patients), calcium antagonists (4 patients) and ami- 
odarone (2 patients). Amiodarone has been shown not to affect 
the relation between the upper limit of vulnerability and 
defibrillation threshold (5). 
Implantation technique and electrode configurations. Pa- 
tients were studied intraoperatively as described previously (5). 
In all patients, a tripolar electrode with a 5-cm defibrillation 
coil (Medtronic model 6966 or 6936, conductive area 4.48 cm 2) 
was positioned in the right ventricular apex through the 
cephalic or subclavian vein. It served as the cathode for the first 
phase of biphasic shocks and for monophasic shocks. 
In the preferred surgical technique (33 patients), the im- 
plantable cardioverter-defibrillator pulse generator and elec- 
trodes were inserted through a single left anterior axillary 
incision using a previously described technique (6). The pulse 
generator was positioned in a retropectoral pocket. In 12 
patients who received the model 7219D pulse generator, a 
patch electrode (Medtronic model 6999, conductive area 
660 mm 2) was positioned eep to the pulse generator to serve 
as the anode; this was the preferred electrode configuration for 
this pulse generator at one institution (Cedars-Sinai Medical 
Center). In four patients, a unipolar electrode with a 5-cm long 
defibrillation coil (Medtronic model 6963, conductive area 
90 mm 2) served as the anode; this was the preferred configu- 
ration at the second institution (Sunrise Medical Center). It 
was positioned through the left subclavian vein with the tip at 
the junction of the innominate vein and superior vena cava 
(high superior vena caval position). In five patients, the patch 
and unipolar electrodes were linked to form the common 
anode. In 12 patients who received a pulse generator with an 
"active can" (Medtronic model 7218C), the titanium shell of 
the pulse generator served as the anode. 
The surgical technique differed in seven patients. In three 
patients, the pulse generator (Medtronic model 7219D) was 
placed in a right retropectoral pocket because surgical consid- 
erations precluded use of the left pectoral region. The unipolar 
electrode served as the anode, and its tip was positioned at the 
junction of the right atrium and superior vena cava. In four 
patients, a larger pulse generator that delivered only monopha- 
sic pulses (Medtronic model 7217B) was positioned in an 
abdominal pocket; both a patch and unipolar electrode formed 
the common anode as described before. At the conclusion of 
the experimental protocol using biphasic shocks, additional 
fibrillation-defibrillation episodes using monophasic shocks 
were performed to satisfy the implantation criterion in these 
four patients. 
Thus, the anode for the first phase of biphasic shocks was a 
retropectoral patch (12 patients), unipolar electrode in the 
superior vena cava (7 patients), combined patch and unipolar 
electrodes (9 patients) or active can (12 patients). 
Determination of upper limit of vulnerability. The main 
features of this method have been described previously (5). 
Pacing was performed through the implanted screw-ring elec- 
trodes at the right ventricular pex. The baseline drive ($1) was 
delivered at a cycle length of 500 ms. Three to six surface 
electrocardiographic leads were recorded simultaneously on a 
physiologic recorder and displayed at 100 mm/s for measure- 
ment purposes. The T wave configurations from all recorded 
leads were inspected to select he lead with the latest peaking 
monophasic T wave. The interval between the pacing stimulus 
and the peak of the T wave in this lead was selected as the 
coupling interval between the last $1 and the first T wave 
shock. 
The first programmed shock was delivered after eight Sas to 
coincide with the peak of the T wave. If fibrillation was not 
induced, subsequent shocks were delivered 20 and 40 ms 
before the peak. If any of the three shocks induced fibrillation, 
the strength of the next shock was increased; if none of the 
three shocks induced fibrillation, the strength of the next shock 
was decreased. 
The shock protocol was a modification of a previously 
described step-down or step-up method (5). The first pro- 
grammed shock strength of 20 J was selected to ensure that the 
upper limit of vulnerability was determined by a step-down 
method in most patients. For patients tested with the 
Medtronic model 2394 external defibrillator, the strength of 
shocks was changed by 5-J steps for energies >15 J. For 
energies between 15 and 5 J, the step-down increment was 5 J, 
followed by a step-up increment of 2.5 J. At 5 J, the step-down 
increment was 2.5 J; and the subsequent step-up or step-down 
increment was 1.25 J. This procedure resulted in a resolution 
of 5 J above the 15-J level; 2.5 J between the 15-J level and the 
5-J level; and 1.25 J below the 5-J level. For patients tested with 
the model 5358 implant support device, the same steps were 
followed, except hat programmed values were rounded to the 
nearest whole number >3 J. 
The upper limit of vulnerability was defined as the weakest 
measured shock strength that did not induce fibrillation after 
delivery of all three shocks at 0, 20, and 40 ms before the peak 
of the Y wave. For the purpose of upper limit of vulnerability 
testing, induced nonsustained polymorphic ventricular tachy- 
cardia with duration >3 s and cycle length <250 ms was 
treated as the induction of fibrillation (5). There was a l-rain 
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interval between the shocks that failed to induce sustained 
ventricular fibrillation. 
Determination of defibrillation threshold. Defibrillation 
threshold testing was performed using the identical method 
used for upper limit of vulnerability testing to permit direct 
comparison of the two measurements. The step-down or 
step-up method was selected for this study as a compromise 
between apure step-down method and a midpoint method (7). 
The pure step-down method permits determination of the 
upper limit of vulnerability with a single episode of fibrillation 
in all patients but requires more episodes of fibrillation to 
determine the defibrillation threshold. The midpoint method 
permits determination of the defibrillation threshold with the 
fewest fibrillation episodes but requires more episodes of 
fibrillation to measure the upper limit of vulnerability. 
Ventricular fibrillation was induced by T wave shocks 
during upper limit of vulnerability testing. A previous tudy (8) 
demonstrated that defibrillation threshold ata determined in
this manner do not differ significantly from defibrillation 
threshold data measured after induction of fibrillation by 
alternating current. If the upper limit of vulnerability was 
determined before the defibrillation threshold was deter- 
mined, subsequent episodes of fibrillation were induced by 
biphasic T wave shocks of 0.2 to 0.6 J. 
The defibrillation threshold was defined as the lowest 
measured shock strength that terminated induced ventricular 
fibrillation after 10 s. There was a 3-rain recovery period after 
each defibrillation shock. 
Probability of defibrillation at upper limit of vulnerability 
or upper limit of vulnerability plus 3 J. After determination f 
the upper limit of vulnerability and defibrillation threshold, 
patients underwent six additional fibrillation-defibrillation ep- 
isodes. The strength of five of the defibrillation shocks was 
programmed to the upper limit of vulnerability. The strength 
of one of the six shocks was selected randomly to be equal to 
the upper limit of vulnerability plus 3 J. 
In addition to this prospective analysis of defibrillation 
shocks with strength equal to the upper limit of vulnerability or 
upper limit of vulnerability plus 3 J, the success rate of shocks 
delivered uring defibrillation threshold testing was analyzed 
retrospectively. Because 2.5-J increments were used for defi- 
brillation threshold testing, a shock was judged equivalent to 
the upper limit of vulnerability plus 3 J for data analysis if its 
programmed strength was 2.5 J greater than the programmed 
strength at the upper limit of vulnerability. 
Pulse generator testing. At one institution (Cedars-Sinai 
Medical Center), the implantable cardiovcrter-defibrillator 
system was tested prospectively using the programmable shock 
strength (9) closest o the upper limit of vulnerability plus 3 J 
in the 30 patients in whom the pulse generator delivered 
biphasic pulses (Medtronic model 7219D or 7218C). If the 
closest programmable shock strength exceeded the upper limit 
of vulnerability plus 3.5 J, the data were not included in the 
statistical analysis (two patients). In the remaining 28 patients, 
the shock strength was within 0.3 J of the upper limit of 
vulnerability plus 3 J; these values were considered equivalent 
to the upper limit of vulnerability plus 3 J for data analysis. 
Detection of fibrillation required sensing of 18 of 24 intervals 
with a cycle length <320 ms at a sensitivity setting of 1.2 inV. 
The duration of fibrillation varied depending on the charge 
time and the detection time (7.5 -+ 2.8 s). 
Data acquisition. This method has been described previ- 
ously for patients tested with the model 2394 external defibril- 
lator (10). Voltage and current waveforms were digitized at 
100 kHz using the MacAdios Board (GW Instruments) and 
recorded on a Macintosh computer. A custom modified oscil- 
loscope mulation program (SuperScopc II, GW Instruments) 
was used to record voltage and current waveforms and to 
detect he leading and trailing edge voltages and currents for 
each phase of the biphasic pulse. Mean resistance was deter- 
mined by averaging point-by-point division of the voltage 
waveform by the current waveform. Stored and delivered 
energies were calculated by previously described methods 
(11,12) using a measured capacitance value of 122 +_ 2/,F (10). 
The model 5358 implant support device automatically mea- 
sures leading edge voltage (V1), trailing edge voltage (Vf) and 
pulse duration (d). It reports stored energy (Es) using the 
formula 
CVi 2 
Es- 2 '  [1] 
where C = output capacitance. A value of 120 tzF is used for 
C in this calculation. For patients tested with this device, we 
used the reported value of stored energy and equation 1 to 
calculate leading edge voltage. Resistance isreported using the 
formula 
d 
R (V~)' [2] 
C.ln 
where C = 132/,F. The actual capacitance was measured by 
determining the tilt and duration of pulses discharged into a 
50-12 load to be 131 _+ 2 /,F. Leading edge current was 
calculated as the ratio of leading edge voltage to resistance. 
Safety. The creatine kinase isoenzyme plasma concentra- 
tion was determined 12 to 18 h postoperatively in 27 of 30 
patients tudied at Cedars-Sinai Medical Center. 
Statistical analysis. Data are presented as mean value _+ 
SD. A p value -<0.05 was used to reject the null hypothesis. 
Confidence intervals for the probability of successful defibril- 
lation at the upper limit of vulnerability were calculated using 
Cochran's method for cluster sampling (13), which uses the 
patient as the unit of analysis. This method is equivalent to 
computing the proportion of successes for each patient and 
basing the confidence interval on the mean value _+ 2 SE, 
where the standard eviation is computed across all 40 pa- 
tients. 
We performed two analyses to evaluate the possible ffect 
of between-patient differences on the probability of defibrilla- 
tion at the upper limit of vulnerability: 1) We calculated the 
expected numbers of patients with no, one, two, three, four or 
five successful shocks at the upper limit of vulnerability assum- 
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Table 1. Mean (-+SD) Defibrillation Threshold and Upper Limit of 
Vulnerability in40 Patients 
DFT ULV p Value 
Stored energy (J) 8.8 ± 5.0 11.3 + 4.6 < 0.001 
Voltage (V) 365 ± 104 420 ± 87 < 0.001 
Current (A) 7.2 ± 2.5 8.3 ± 2.3 < 0.001 
Resistance 0"l) 52 ± 10 52 ± 10 0.94 
DFT = defibrillation threshold; ULV = upper limit of vulnerability. 
ing no between-patient differences and the observed overall 
success rate. For this calculation, we assumed binomial varia- 
tion. The results of this calculation were then compared with 
the observed number of patients with no, one, two, three, four 
or five successful shocks. 2) We estimated the effect of 
electrode configuration and clinical variables on the number of 
successful defibrillations per patient. Nominal variables (elec- 
trode configuration, gender, presenting arrhythmia, type of 
structural heart disease and heart failure class) were analyzed 
by analysis of variance with each variable as a factor and the 
number of successful defibrillations per patient as the depen- 
dent variable. Continuous variables (age and left ventricular 
ejection fraction) were evaluated by linear egression analysis. 
Resu l ts  
Defibrillation threshold and upper limit of vulnerability. 
Table 1 summarizes values for defibrillation threshold and 
upper limit of vulnerability in all 40 patients. The Pearson 
correlation coefficient between defibrillation threshold and 
upper limit of vulnerability was 0.89 for stored energy (p < 
0.001) and 0.88 for voltage (p < 0.001). The upper limit of 
vulnerability was greater than or equal to the defibrillation 
threshold in 38 (95%) of 40 patients and was less than the 
defibrillation threshold by 2.6 J in one patient and 3.0 J in 
another (5%). The mean defibrillation threshold was 2.5 J 
lower than the mean upper limit of vulnerability (range -3.0 to 
8.0 J). 
Success of defibrillation shocks at upper limit of vulnera- 
bility. Overall, 180 (90%) of the 200 defibrillation test shocks 
with strength equal to the upper limit of vulnerability resulted 
in successful defibrillation. All five defibrillation test shocks 
with strength equal to the upper limit of vulnerability were 
successful in 24 patients (60%); four of five were successful in 
12 patients (30%); and three of five were successful in 4 
patients (10%). The 95% confidence intervals based on the 
proportion of successes in 40 patients were 86% to 94%. 
Figure 1 shows the number of successful shocks per patient, 
stratified by electrode configuration. The percent of successful 
shocks was not significantly different among electrode config- 
urations, ranging from a low of 88% for the active can 
configuration to94% for the superior vena caval configuration. 
None of the clinical variables measured correlated with the 
percent of successful shocks at the upper limit of vulnerability. 
Analysis of the expected number of patients with no, one, two, 
three, four or five successful shocks at the upper limit of 
251 • RV -> Patch+SVC (n = 9) 
20 [ ]  RV -> SVC (n = 7) 
i [ ]  RV-> Patch (n = 12) 
~15 [ ]  RV-> CAN (n = 12) 
I I I I I I 
0 1 2 3 4 5 
Number of Successful Defibrillations 
Figure 1. Histogram showing the number of successful defibrillation 
test shocks with strength equal to the upper limit of vulnerability for all 
40 patients stratified by the anodal electrode for the first phase of 
biphasic shocks. In all patients, the electrode in the right ventricle 
(RV) was the cathode for the first phase of biphasic shocks. The 
number of successful shocks was 53 (88%) of 60 for the 12 patients 
with active can (CAN) electrodes, 54(90%) of 60 for the 12 patients 
with a patch electrode, 33 (94%) of 35 for the 7 patients with an 
electrode inthe superior vena caval electrode (SVC) and 40 (89%) of 
45 for the 9 patients with both patch and superior vena caval 
electrodes. 
vulnerability provided further support for the absence of 
significant between-patient differences. Assuming a true prob- 
ability of success of 90% and no between-patient differences, 
we expect 0.3 patients with two or fewer successes, 2.9 patients 
with three successes, 13.1 patients with four successes and 23.7 
patients with five successes (13). These numbers are close to 
the observed values in the present study. 
During defibrillation threshold testing, all patients received 
an additional defibrillation shock with strength equal to the 
upper limit of vulnerability. Post hoc analysis howed that 37 
(92%) of these 40 shocks were successful. 
Success of defibrillation shocks at upper limit of vulnera- 
bility plus 3 J. Table 2 shows the stored energy and voltage for 
shocks considered equivalent to the upper limit of vulnerability 
plus 3 J. For the 40 prospective, randomized efibrillation 
shocks, this value corresponded to 56 _+ 10 V (range 40 to 85) 
above the upper limit of vulnerability. The success rate was 
100% for these 40 shocks. The upper limit of vulnerability plus 
3 J exceeded the defibrillation threshold by ->10 J in only one 
patient (3%). The success rate was also 100% for the 28 shocks 
delivered prospectively during testing of the implanted pulse 
generator. 
Retrospective analysis of shocks delivered uring the defi- 
brillation threshold protocol identified 31 patients who re- 
ceived a defibrillation shock programmed to the upper limit of 
vulnerability plus 2.5 J. All were successful. Thus, the overall 
success rate was 100% for all 99 defibrillation shocks at the 
upper limit of vulnerability plus 3J. This includes 40 shocks 
tested prospectively during repeated assessment of defibrilla- 
tion efficacy, 28 shocks tested prospectively during pulse 
generator testing and 31 shocks used for defibrillation thresh- 
old testing and analyzed retrospectively. 
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Table 2. Measured Values for Defibrillation Shocks Programmed to Upper Limit of Vulnerability Plus 
3 J (mean - SD) 
Shock - ULV 
No. of Pts E s (J) Voltage (V) E s (J) Voltage (V) 
Randomized shocks 40 14.3 _+ 4.6 476 _+ 77 3.0 + 0.2 56 _+ 10 
DFT shocks 31 13.7 - 4.5 460 +_ 79 2.6 -+ 0.2 47 -+ 8 
ICD test shocks 28 14.6 - 4.7 NM 3.1 _+ 0.3 NM 
DFT = defibrillation threshold; Es = stored energy; ICD = implantable cardioverter-defibrillator; NM = not 
measured; I ts  = patients; ULV = upper limit of vulnerability. 
Safety. No patient developed a decrease in arterial pres- 
sure >20% or 1 mm of ST segment depression that persisted 
>30 s. The creatine kinase myocardial isoenzyme plasma 
concentration (1.2 +- 0.5 ng/ml) did not exceed the upper limit 
of normal in any of the 27 patients in which it was measured. 
All patients had an uncomplicated clinical course after opera- 
tion and postoperative electrophysiologic testing. 
Discuss ion  
There are two principal findings of this prospective study 
regarding a simple, clinically applicable measure of the upper 
limit of vulnerability: 1) The upper limit of vulnerability is an 
accurate stimator of the shock strength that defibrillates with 
a probability of 90% (DFT90). 2) Shocks with strength equal to 
the upper limit of vulnerability plus 3 J had a defibrillation 
success rate of 100%. 
Direct measurement of defibrillation efficacy. Selection of 
a clinical method to measure defibrillation efficacy requires a 
compromise between accuracy and safety. Direct determina- 
tion of a dose-response curve is most accurate (7,14). This 
method generally is considered unsafe in humans because the 
number of required fibrillation-defibrillation episodes is ex- 
cessive. However, even an accurate stimate of a single point 
on the dose-response curve requires many fibrillation- 
defibrillation episodes (15,16). The established up-down 
method (4,16) can provide an accurate stimate of the DFT50, 
but it does not provide a good estimate of the more clinically 
relevant shock strengths associated with a high probability of 
success, such as the DFT90 (17). Single-point determinations 
of defibrillation threshold are used commonly to decrease the 
number of fibrillation-defibrillation episodes (7). However, 
the probability of defibrillation success at the single-point 
defibrillation threshold is highly variable (18); multiple 
fibrillation-defibrillation episodes are still necessary, and re- 
ported complications include cerebral hypoperfusion (7,19), 
myocardial ischemia (20), systemic hypoperfusion (28), dimin- 
ished left ventricular function (29-31), prolonged circulatory 
arrest (21), and death (22,23). The Bayesian method of Malkin 
and co-workers (17,24) can provide a good estimate of clini- 
cally relevant points on the dose-response curve with only four 
fibrillation-defibrillation episodes, but it has not been applied 
widely. 
Upper limit of vulnerability as estimator of defbrillation 
elficacy. The upper limit of vulnerability has been proposed as 
an indirect measure of defibrillation efficacy because it corre- 
lates with the defibrillation threshold and can be determined 
with a single episode of fibrillation if a step-down protocol is 
used. However, some previous methods for determining the 
upper limit of vulnerability were impractical for clinical use 
because they required scanning the T wave with many shocks 
(2,3). The results of others did not correlate closely enough 
with the defibrillation threshold to substitute for it reliably 
(4,25,26). 
We reported previously (27) that a minimum of three 
shocks are required for a clinically relevant correlation be- 
tween the upper limit of vulnerability and the defibrillation 
threshold (5) and that the upper limit of vulnerability deter- 
mined by this method is highly reproducible. However, because 
it was not known whether the upper limit of vulnerability 
identified a shock strength associated with a predictable prob- 
ability of defibrillation, the impact of these findings has been 
limited. 
The present study demonstrates that the upper limit of 
vulnerability measured by the three-shock method identifies a 
clinically relevant shock strength associated with a high and 
highly predictable probability of defibrillation--the DFT90. 
Our data show that this estimate of the DFT90 is sufficiently 
accurate such that direct measurement of defibrillation efficacy 
is unnecessary in most clinical situations. Depending on the 
level of accuracy required, the three-shock upper limit of 
vulnerability also may he used to compare defibrillation effi- 
cacy under different experimental conditions with the fewest 
fibrillation episodes. However, it is possible that other methods 
for measuring the upper limit of vulnerability may provide a 
better estimate of defibrillation efficacy than the method used 
in this study. 
Implications for programming implantable cardioverter- 
defibrillators. Ideally, the first shock from an implantable 
cardioverter-defibrillator should have a high probability of 
success but avoid excessive shock strengths that produce 
unnecessary battery depletion and may be harmful. The shock 
strengths required for defibrillation vary widely among patients 
(28), and accurate knowledge of patient-specific defibrillation 
efficacy is required to permit optimal programming. 
The results of the present study indicate that the upper limit 
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of vulnerability plus 3 J is a good estimate of the minimal acute 
safety margin appropriate for implantable cardioverter- 
defibrillator first shocks. This shock strength is close to that 
proposed by Bernstein et al. (29) for a different ransvenous 
implantable cardioverter-defibrillator system. They reported a
100% success rate for shocks at the DFT80 plus 100 V. The 
prospective findings of the present study expand the retrospec- 
tive observation of our previous tudy (5). In that study, post 
hoc analysis of shocks delivered uring defibrillation threshold 
testing found a success rate of 100% for 28 biphasic shocks 
with strength equal to the upper limit of vulnerability plus 5 J. 
Although the present study demonstrates that the upper 
limit of vulnerability predicts the minimal acute safety margin 
for programming of implantable cardioverter-defibrillators, 
the long-term stability of this safety margin is unknown. The 
minimal shock strength required to defibrillate with a high 
probability of success may vary over time because of changes in 
physiologic or pathologic onditions. We do not know whether 
a shock strength equal to the acute upper limit of vulnerability 
plus 3 J will provide an adequate long-term safety margin. 
Prospective assessment of the efficacy of implantable 
cardioverter-defibrillator shocks programmed to the upper 
limit of vulnerability plus 3 J is necessary before this guideline 
is applied clinically. 
Further, data regarding the relation between the upper 
limit of vulnerability and the defibrillation threshold for long- 
term implanted electrode systems are limited. In a preliminary 
report, Martin et al. (30) reported good correlation. However, 
we do not know whether the long-term upper limit of vulner- 
ability is a good estimator of the long-term DFT90. 
Theoretical considerations. According to the upper limit 
of vulnerability hypothesis of defibrillation, a shock always 
defibrillates if it terminates all reentrant wavefronts and pro- 
duces a field above the upper limit of vulnerability throughout 
both ventricles (3,31-33). To the extent hat the upper limit of 
vulnerability in paced rhythm reflects the upper limit of 
vulnerability during fibrillation, defibrillation shocks with 
strength equal to the upper limit of vulnerability in paced 
rhythm should have a high and highly predictable probability 
of success. 
Safety. Although determination of the upper limit of vul- 
nerability requires multiple test shocks in paced rhythm, the 
interval between shocks can be timed to minimize the risks of 
frequent shocks (34). Clinical and creatine kinase isoenzyme 
data from the present study and clinical data from a previous 
study (5) indicate no adverse ffects of upper limit of vulner- 
ability testing combined with limited defibrillation threshold 
testing. However, frequent 35-J shocks in sinus rhythm have 
been reported to decrease myocardial lactate extraction in 
dogs (35), and a rigorous comparison of the safety of upper 
limit of vulnerability and defibrillation threshold testing has 
not been performed. 
Study limitations. Shock protocol The upper limit of vul- 
nerability can be determined with a single episode of fibrilla- 
tion only if a pure step-down method is used. The step-down or 
step-up method used in the present study required either one 
or two episodes of fibrillation to determine the upper limit of 
vulnerability. We selected itbecause we wished to use the same 
method to measure the upper limit of vulnerability and the 
defibrillation threshold, and this method reduced the number 
of episodes of fibrillation during defibrillation threshold test- 
ing. Use of a pure step-down method would have required 
more shocks in paced rhythm to determine the upper limit of 
vulnerability with the same resolution. We have not evaluated 
the safety of such a protocol directly, but all the additional 
required shocks in paced rhythm are 12.5 J or weaker and are 
not likely to cause hemodynamic compromise or myocardial 
damage. Alternatively, determining the upper limit of vulner- 
ability with a resolution of 5 J would require a single episode of 
fibrillation and fewer shocks in paced rhythm than the method 
used in the present study. Such a protocol would most likely 
result in a less accurate stimate of DFT90, which may be 
acceptable for clinical purposes. 
Electrode configuration. The present study included pa- 
tients with different electrode configurations. Although the 
cathode for the first phase of biphasic shocks was the same in 
all patients, the anode varied depending on the configuration 
used. However, the success rate for defibrillation shocks at the 
upper limit of vulnerability was similar for all configurations 
tested. Thus, the results do not depend strongly on the clinical 
electrode configuration used, provided that pacing is per- 
formed from the right ventricular apex and the cathode for the 
first phase of biphasic shocks is positioned at the right ventric- 
ular apex. 
Shock waveform. Results regarding defibrillation success at 
the upper limit of vulnerability plus 3 J apply only to pulses 
delivered from 120- to 132-t.tF capacitors; the safety margin for 
capacitors of different sizes may be defined better by voltage 
than by energy. 
Effect of antiarrhythmic drugs. Data regarding the effect of 
antiarrhythmic drugs on the relation between the upper limit 
of vulnerability and defibrillation threshold are limited. Lido- 
caine changes this relation (8), but amiodarone (5) and 
procainamide (36) do not. Our results may not apply to 
patients taking antiarrhythmic drugs. 
Conclusions. The upper limit of vulnerability provides a 
good estimate of the DFT90 with a minimal number of 
fibrillation episodes. A strength of 3 J above the upper limit of 
vulnerability is a good estimate of the minimal short-term 
safety margin for implantable cardioverter-defibrillator first 
shocks. 
We thank Janet Elashoff. PhD for statistical consultation. 
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